Q2 2019 13F Holders as of 30 Jun 2019
-
Type / Class
-
Debt / NOTE 3.250% 7/0
-
Market price (% of par)
-
89.21%
-
Total 13F principal
-
$417,577,832
-
Principal change
-
-$38,065,168
-
Total reported market value
-
$386,205,424
-
Number of holders
-
48
-
Value change
-
-$39,428,176
-
Number of buys
-
18
-
Number of sells
-
19
Institutional Holders of INTERCEPT PHARMACEUTICALS IN - NOTE 3.250% 7/0 as of Q2 2019
As of 30 Jun 2019,
INTERCEPT PHARMACEUTICALS IN - NOTE 3.250% 7/0 was held by
48 institutional
bondholders
reporting positions in Form 13F filings.
These institutions reported holding
$417,577,832
in principal (par value) of the bond.
The largest 10 bondholders included
Allianz Asset Management GmbH, DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), ADVENT CAPITAL MANAGEMENT /DE/, WOLVERINE ASSET MANAGEMENT LLC, MORGAN STANLEY, MACKAY SHIELDS LLC, AMERIPRISE FINANCIAL INC, Graham Capital Management, L.P., LAZARD ASSET MANAGEMENT LLC, and STATE STREET CORP.
This page lists
48
institutional bondholders reporting positions
for the Q2 2019 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price (% of par)
|
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.